Recent advances in epitope design for immunotherapy of cancer

Recent Patents on Anti-Cancer Drug Discovery

Volumn 4, Issue 3, 2009, Pages 227-240

  Chiarella, Pieranna ^a,b   Massi, Emanuela ^a,b   De Robertis, Mariangela ^a,b   Fazio, Vito M ^a,c   Signori, Emanuela ^a,b  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b CNR   (Italy)

^c CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

'In silico' prediction; Cancer; Clinical trials; Epitope enhancement; Immunotherapy; Tumuor antigens; Vaccine; Webbased tools

Indexed keywords

ALLOGENEIC CELL VACCINE; AUTOLOGOUS CELL VACCINE; CANCER VACCINE; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; DNA VACCINE; EPITOPE; EPITOPE BASED CANCER VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; ORZEL; SUBUNIT VACCINE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CLINICAL TRIAL; COLORECTAL CANCER; COMPUTER PREDICTION; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; HUMAN; IMMUNOGENICITY; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; PATENT; PRIORITY JOURNAL; REVIEW; STOMACH CANCER; VACCINE PRODUCTION; WEB BROWSER;

ALGORITHMS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; EPITOPES; HUMANS; PATENTS AS TOPIC;

EID: 70350766682     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489209789206922     Document Type: Review

References (130)

1. Global Cancer Facts & Figures 2007. American Cancer Society.
2. Reiman JM, Kmieciak M, Manjili MH, Knutson KL. Tumor immunoediting and immunosculpting pathways to cancer progression. Semin Cancer Biol 2007; 17: 275-287.
3. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immuno-editing. Annu Rev Immunol 2004; 22: 329-360.
4. Dunn GP, Old LJ, Schreiber RD. The Immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004; 21: 137-148.
5. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005; 5: 263-274.
6. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: Mapping the way. Nat Med 2004; 10: 475-480.
7. Melief CJ, Toes RE, Medema JP, et al. Strategy for immunotherapy of cancer. Adv Immunol 2000; 75: 235-282.
8. Bronte V. Th17 and cancer: Friends or foes? Blood 2008; 112: 214.
9. Muranski P, Boni A, Antony PA, et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 2008; 112: 362-373.
10. Bonnotte B, Favre N, Moutet M, et al. Bcl-2-Mediated Inhibition of apoptosis prevents immunogenicity and restores tumorigenicity of spontaneously regressive tumors. J Immunol 1998; 161: 1433-1438.
11. Bruserud Ø, Ersvaer E, Olsnes A, Gjertsen BT. Anticancer immunotherapy in combination with proapoptotic therapy. Curr Cancer Drug Targets 2008; 8: 666-675.
12. Garnett CT, Greiner JW, Tsang KY, et al. TRICOM vector based cancer vaccines. Curr Pharm Des 2006; 12: 351-361.
13. June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest 2007; 117: 1466-1476.
14. + T cells in the treatment of metastatic melanoma. Nat Clin Pract Oncol 2008; 5: 696-697.
15. Foss FM. DAB(389) IL-2 (ONTAK): A novel fusion toxin therapy for lymphoma. Clin Lymphoma 2000; 1: 110-106.
16. Curiel TJ, Wei S, Dong H, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumour immunity. Nat Med 2004; 9: 562-567.
17. Uyttenove C, Pilotte L, Theate I, et al. Evidence for a tumoral immune resistance mechanism based on tryptofan degradation by indoleamine 2,3-dioxigenase. Nat Med 2003; 9: 1269-1274.
18. Wang T, Niu G, Kortylewski M, et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumour cells. Nat Med 2004; 10: 48-54.
19. Park JM, Terabe M, Donaldson DD, Forni G, Berzofsky JA. Natural immunosurveillance against spontaneous, autochthonous breast cancers revealed and enhanced by blockade of IL-13-mediated negative regulation. Cancer Immunol Immunother 2008; 57: 907-912.
20. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005; 23: 1126-1136.
21. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002; 2: 750-763.
22. Sharma SK, Pedley RB, Bhatia J, et al. Sustained tumor regression of human colorectal cancer xenograft using a multifunctional mannosylated fusion protein in antibody-directed enzyme prodrug therapy. Clin Cancer Res 2005; 11: 814-825.
23. Oldham RK, Dillman RO. Monoclonal antibodies in cancer therapy: 25 years of progress. J Clin Oncol 2008; 26: 1774-1777.
24. Pardoll DM. Spinning molecular immunology into successfull immunotherapy. Nat Rev Immunol 2002; 2: 227-238.
25. Yu P, Lee Y, Liu W, et al. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol 2005; 5: 141-149.
26. Ochsenbein AF, Sierro S, Odermatt B, et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 2001; 411: 1058-1064.
27. Klebanoff CA, Gattinoni L, Restifo NP. CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev 2006; 211: 214-224.
28. Kwissa M, Kasturi SP, Pulendran B. The science of adjuvants. Exp Rev Vacc 2007; 6: 673-684.
29. Brinkman JA, Fausch SC, Weber JS, Kast WM. Peptide-based vaccines for cancer immunotherapy. Exp Opin Biol Ther 2004; 4: 181-198.
30. Chiarella P, Massi E, De Robertis M, Signori E, Fazio VM. Adjuvants in vaccines and for immunisation: Current trends. Exp Opin Biol Ther 2007; 7: 1551-1562.
31. de Gruijl TD, van den Eertwegh AJ, Pinedo HM, Scheper RJ. Whole-cell cancer vaccination: From autologous to allogeneic tumor- and dendritic cell-based vaccines. Cancer Immunol Immunother 2008; 57: 1569-1577.
32. Fournier P, Schirrmacher V. Randomized clinical studies of antitumor vaccination: State of the art in 2008. Expert Rev Vacc 2009; 8: 51-66.
33. Harrop R, John J, Carroll MW. Recombinant viral vectors: Cancer vaccines. Adv Drug Deliv Rev 2006; 58: 931-947.
34. Rice J, Ottensmeier CH, Stevenson FK. DNA vaccines: Precision tools for activating effective immunity against cancer. Nat Rev Cancer 2008; 8: 108-120.
35. Abrams SI, Schlom J. Rational antigen modification as a strategy to upregulate or downregulate antigen recognition. Curr Opin Immunol 2000; 12: 85-91.
36. Chiarella P, Massi E, De Robertis M, Fazio VM, Signori E. Strategies for effective naked-DNA vaccination against infectious diseases. Recent Pat Anti-Infect Drug Discov 2008; 3: 93-101.
37. Rosenberg SA, Zhai Y, Yang JC, et al. Immunizing patients with metastatic melanoma using recombinant adenovirus encoding MART-1 or gp-100 melanoma antigens. J Natl Cancer Inst 1998; 90: 1894-1900.
38. Gilboa E, Nair SK, Lyerly KH. Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol Immunother 1998; 46: 82-88.
39. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007; 449: 419-426.
40. Tacken PJ, Jolanda I, de Vries M, Torensma R, Figdor CG. Dendritic-cell immunotherapy: From ex vivo loading to in vivo targeting. Nat Rev Immunol 2007; 7: 790-802.
41. Cavallo F, Offringa R, van der Burg SH, Forni G, Melief CJ. Vaccination for treatment and prevention of cancer in animal models. Adv Immunol 2006; 90: 175-213.
42. Sette A, Fikes J. Epitope-based vaccines: An update on epitope identification, vaccine design and delivery. Curr Opin Immunol 2003; 15: 461-470.
43. Lundegaard C, Lund O, Kesmir C, Brunak S, Nielsen M. Modeling the adaptive immune system: Predictions and simulations. Bioinformatics 2007; 23: 3265-3275.
44. Lundegaard C, Nielsen M, Lund O. The validity of predicted T-cell epitopes. Trends Biotechnol 2006; 24: 537-538.
45. Kessler JH, Melief CJ. Identification of T-cell epitopes for cancer immunotherapy. Leukemia 2007; 2: 1859-1874.
46. + T-cell-based cancer vaccines. Adv Cancer Res 2006; 95: 203-247.
47. Yewdell JW, Bennink JR. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu Rev Immunol 1999; 17: 51-88.
48. Larsen MV, Lundegaard C, Lamberth K, Buus S, Lund O, Nielsen M. Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction. BMC Bioinform 2007; 8: 424.
49. Dyall R, Bowne WB, Weber LW, et al. Heteroclitic immunization induces tumor immunity. J Exp Med 1998; 188: 1553-15561.
50. Butler NS, Theodossis A, Webb AI, et al. Prevention of cytotoxic T cell escape using a heteroclitic subdominant viral T cell determinant. PloS Pathol 2008; 4: e1000186. [Epub 2008 Oct 24].
51. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanović S. SYFPEITHI: Database for MHC ligands and peptide motifs. Immunogenetics 1999; 50: 213-219.
52. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLAA2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994; 152: 163-175.
53. Sturniolo T, Bono E, Ding J, et al. Generation of tissue specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat Biotechnol 1999; 17: 555-561.
54. Singh H, Raghava GP. ProPred: Prediction of HLA-DR binding sites. Bioinformatics 2001; 17: 1236-1237.
55. Sette A, Newman M, Livingston B, et al. Optimizing vaccine design for cellular processing, MHC binding and TCR recognition. Tissue Antigens 2002; 59: 443-451.
56. Blancou P, Mallone R, Martinuzzi E, et al. Immunization of HLA class I transgenic mice identifies autoantigenic epitopes eliciting dominant responses in type 1 diabetes patients. J Immunol 2007; 178: 7458-7466.
57. Nagorsen D, Marincola FM. Analyzing T cell responses: How to analyze cellular immune responses against tumour associated antigens. Springer ed 2005; 103-122.
58. Rinaldi M, Fioretti D, Iurescia S, et al. Anti-tumor immunity induced by CDR3-based DNA vaccination in a murine B-cell lymphoma model. Biochem Biophys Res Commun 2008; 370: 279-284.
59. Parker JMD, Guo D, Hodges RS. New hydrophilicity scale derived from high performance liquid chromatography peptide retention data: Correlation of predicted surface residues with antigenicity and X-ray-derived accessible sites. Biochemistry 1986; 25: 5425-5432.
60. Karplus PA, Schulz GE. Prediction of chain flexibility in proteins: A tool for the selection of peptide antigen. Naturwissenschaften 1985; 72: 212-213.
61. Emini EA, Hughes JV, Perlow DS, Boger J. Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide. J Virol 1985; 55: 836-839.
62. Pellequer JL, Westhof E, Regenmortel MHV. Correlation between the location of antigenic sites and the prediction of turns in proteins. Immunol Lett 1993; 36: 83-99.
63. Janin J, Wodak S. Conformation of amino acid side-chains in proteins. J Mol Biol 1978; 125: 357-386.
64. Ponnuswamy PK, Prabhakaran M, Manavalan P. Hydrophobic packing and spatial arrangement of amino acid residues in globular proteins. Biochim Biophysic Acta 1980; 623: 301-316.
65. Kolaskar AS, Tongaonkar PC. A semi-empirical method for prediction of antigenic determinants on protein antigens. FEBS 1990; 276: 172-174.
66. Saha S, Raghava GPS. BcePred. Prediction of Continuous B-Cell Epitopes in Antigenic Sequences Using Physico-chemical Properties. Lect Notes Comput Sci. Springer 2004; 197-204.
67. Sette, A., Chesnut, R., Livingston, B.D., Baker, D.M., Newman, M.J.: US20087462354 (2008).
68. Simard, J.J.L., Diamond, D.C.: US20056861234 (2005).
69. Kokolus, W.J., Fritsche, H.A., Johnston, D.A.: US20006070126 (2000).
70. Zauderer, M.: US20056872518 (2005).
71. Fridman, A., Bagchi, A., Bailey, W.: US20060257944 (2006).
72. Simard, J.J.L., Diamond, D.C., Liu, L., Xie, Z.: US20050221440 (2005).
73. Kwok, W.W., Nepom, G., Gebe, J., Reijonen, H., Liu, A.: US20060240482 (2006).
74. Cochlovius B, Stassar M, Christ O, et al. in vitro and in vivo Induction of a Th cell response toward peptides of the melanoma-associated glycoprotein 100 protein selected by the TEPITOPE program. J Immunol 2000; 165: 4731-4741.
75. Simard, J.J.L., Diamond, D.C.: US20050069982 (2005).
76. Kosmatopoulos, K., Tourdot, S., Scardino, A., Gross, A.D.: US20087425606 (2008).
77. van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643-1647.
78. Sahin U, Türeci O, Pfreundschuh M. Serological identification of human tumor antigens. Curr Opin Immunol 1997; 9: 709-716.
79. Heckerman, D.E., Kadie, C.M., Listgarten, J., Zaitlen, N.A., Jojic, N.: US20080172215 (2008).
80. Hanabuchi, S., Ohashi, T., Kannagi, M.: US20040171090 (2004).
81. Morton, D.L.: US5993828 (1999).
82. Van D., Burg S.H., Kast, W.M., Toes, R.E., Offringa, R., Melief, C.J.M.: US20070025968 (2007).
83. Babe, L.M., De Young, L.M., Harding, F.A., Huang, M.T.F., Power, S.D., Stickler, M.: US20070037151 (2007).
84. Hoon, D.S.B., Kaneda, Y.: US20026472375 (2002).
85. Ditzel, H., Jensenius, J.C.: US20050048070 (2005).
86. Ward, R.L.: US20080241177 (2008).
87. Keogh E, Fikes J, Southwood S, Celis E, Chesnut R, Sette A. Identification of new epitopes from four different tumor-associated antigens: Recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity. J Immunol 2001; 167: 787-796.
88. Schmitz J, Reali E, Hodge JW, et al. Identification of an interferon-inducible carcinoembryonic antigen (CEA) CD8R T-cell epitope, which mediates tumor killing in CEA transgenic mice. Cancer Res 2002; 62: 5058-5064.
89. Scardino A, Alves P, Gross DA, et al. Identification of HER-2/neu immunogenic epitopes presented by renal cell carcinoma and other human epithelial tumors. Eur J Immunol 2001; 31: 3261-3270.
90. Umano Y, Tsunoda T, Tanaka H, et al. Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild-type p53. Br J Cancer 2001; 84: 1052-1057.
91. Tanaka H, Tsunoda T, Nukaya I, et al. Mapping the HLA-A24-restricted T-cell epitope peptide from a tumor-associated antigen HER2/neu: Possible immunotherapy for colorectal carcinomas. Br J Cancer 2001; 84: 94-99.
92. Riley JP, Rosenberg SA, Parkhurst MR. Identification of a new shared HLA-A2.1 restricted epitope from the melanoma antigen tyrosinase. J Immunother 2001; 24: 212-220.
93. Kiessling A, Schmitz M, Stevanovic S, et al. Prostate stem cell antigen: Identification of immunogenic peptides and assessment of reactive CD8R T cells in prostate cancer patients. Int J Cancer 2002; 102: 390-397.
94. Lu J, Celis E. Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen. Cancer Res 2002; 62: 5807-5812.
95. Valmori, D., Cerrotini, J.C., Romero, P.: US20026417165 (2002).
96. Sette, A., Sidney, J., Southwood, S., Celis, E.: US20077252829 (2007).
97. Fikes, J.D., Livingston, B.D., Sette, A.D., Sidney, J.C.: US20026464980 (2002).
98. Somasundaram R, Swoboda R, Caputo L, et al. Human leukocyte antigen-A2-restricted CTL responses to mutated BRAF peptides in melanoma patients. Cancer Res 2006; 66: 3287-3293.
99. Herlyn, D., Somasundaram, R., Otvos, L.: WO2007002811 (2007).
100. Scheinberg, D.A., Sette, A., Bocchia M.: US20006156316 (2000).
101. Sette A., Sidney, J., Southwood, S., Chestnut, R., Celis, E., Grey, H.M.: US20067026443 (2006).
102. Sette, A., Sidney, J., Southwood, S., Vitiello, M.A., Livingston, B.D., Celis, E., Kubo, R.T., Grey, H.M., Chesnut, R.W.: US20046689363 (2004).
103. Wang RF. The role of MHC class II-restricted tumor antigens and CD4R T cells in antitumor immunity. Trends Immunol 2001; 22: 269-276.
104. Zarour HM, Maillere B, Brusic V, et al. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2- type tumor-reactive CD4RT cells. Cancer Res 2002; 62: 213-218.
105. Kierstead LS, Ranieri E, Olson W, et al. gp100/pmel17 and Tyrosinase encode multiple epitopes recognized by Th1-type CD4RT cells. Br J Cancer 2001; 85: 1738-1745.
106. Chaux P, Lethé B, Van Snick J, et al. A MAGE-1 peptide recognized on HLA-DR15 by CD4R T cells. Eur J Immunol 2001; 31: 1910-1916.
107. Kobayashi H, Song Y, Hoon DSB, Appella E, Celis E. Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles. Cancer Res 2001; 61: 4773-4778.
108. Consogno G, Manici S, Facchinetti V, et al. Identification of immunodominant regions among promiscuous HLA-DRrestricted CD4R T-cell epitopes on the tumor antigen MAGE-3. Blood 2003; 101: 1038-1044.
109. Kobayashi H, Omiya R, Ruiz M, et al. Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen. Clin Cancer Res 2002; 8: 3219-3225.
110. McNeel DG, Nguyen LD, Disis ML. Identification of T helper epitopes from prostatic acid phosphatase. Cancer Res 2001; 61: 5161-5167.
111. Vissers JLM, de Vries IJM, Engelen LPH, et al. Renal cell carcinoma-associated antigen G250 encodes a naturally processed epitope presented by human leukocyte antigen-dr molecules to CD4R T lymphocytes. Int J Cancer 2002; 100: 2441-2444.
112. Knutson KL, Schiffman K, Disis ML. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 2001; 107: 477-484.
113. Kobayashi H, Lu J, Celis E. Identification of helper T-cell epitopes that encompass or lie proximal to cytotoxic T-cell epitopes in the gp100 melanoma tumor antigen. Cancer Res 2001; 61: 7577-7584.
114. Chen YT, Scanlan MJ, Salin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1997; 94: 1914-1918.
115. Wang, R., Rosenberg, S.A., Zeng, G.: US20050136402 (2005).
116. Topalian SL, Gonzales MI, Parkhurst M, et al. Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp Med 1996; 183: 1965-1971.
117. Li K, Adibzadeh M, Halder T, et al. Tumour-specific MHC class-II-restricted responses after in vitro sensitization to synthetic peptides corresponding to gp100 and annexin II eluted from melanoma cells. Cancer Immunol Immunother 1998; 47: 32-38.
118. Chaux P, Vantomme V, Stroobant V, et al. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J Exp Med 1999; 189: 767-778.
119. Manici S, Sturniolo T, Imro MA, et al. Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. J Exp Med 1999; 189: 871-876.
120. Wang RF, Wang X, Atwood AC, Topalian SL, Rosenberg SA. Cloning genes encoding MHC class II-restricted antigens: Mutated CDC27 as a tumor antigen. Science 1999; 284: 1351-1354.
121. Wang R-F, Wang X, Rosenberg SA. Identification of a novel MHC class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4+ T cells. J Exp Med 1999; 189: 1659-1668.
122. Sette, A., Sidney, J., Southwood S.: US20026413517 (2002).
123. Sette, A., Gaeta, F., Grey, H.M., Sidney, J., Alexander J.L.: US20077202351 (2007).
124. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4: 321-327.
125. Belli F, Testori A, Rivoltini L, et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: Clinical and immunologic findings. J Clin Oncol 2002; 20: 4169-4180.
126. Mazzaferro V, Coppa J, Carrabba MG, et al. Vaccination with autologous tumor-derived heatshock protein gp96 after liver resection for metastatic colorectal cancer. Clin Cancer Res 2003; 9: 3235-3245.
127. Pilla L, Patuzzo R, Rivoltini L, et al. A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients. Cancer Immunol Immunother 2006; 55: 958-968.
128. Hall T, Wolpert EZ, van Veelen P, et al. Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants. Nat Med 2006; 12: 417-424.
129. Pashine A, Valiante MN, Ulmer JB. Targeting the innate immune response with improved vaccine adjuvants. Nat Med 2005; 11: S63-S68.
130. Rosenberg S, Yang J, Restifo N. Cancer immunotherapy: Moving beyond current vaccines. Nat Med 2004; 10: 909-915.